Ding Yuan, Wu Tianchun, Zhang Wenyan, Zhang Sitong, Wang Weilin
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China.
Ann Transl Med. 2019 Jun;7(11):243. doi: 10.21037/atm.2019.05.22.
In the model for end-stage liver disease (MELD) score, renal function was well thought to be associated with the prognosis of liver recipients. Serum cystatin C (CystC)-based equations were considered more accurate for calculating estimated glomerular filtration rate (eGFR) than creatinine (Pcr) based equations. Thus, we aimed to assess the association between eGFR estimated by chronic kidney disease epidemiology collaboration (CKD-EPI)-CystC equation and post-transplantation mortality.
From January 2015 to January 2018, prior to liver transplantation (LT) and other clinical parameters, CystC was collected in all 307 consecutive patients who underwent LT at our center. Patients were divided into four groups according to the Kidney Disease Outcomes Quality Initiative (KDOQI) classification.
Based on CKD-EPI-CystC and the KDOQI classification, 117 patients (38.1%) were stage I, 76 (24.8%) were stage II, 85 (27.7%) were stage III, and 29 (9.4%) were stage IV-V. After univariate and multivariate analysis, MELD score [hazard ratio (HR) =1.035; 95% confidence interval (CI), 1.006-1.066; P=0.018], associated HCC (HR =2.314; 95% CI, 1.253-4.273; P=0.007), and KDOQI stage III (HR =1.850; 95% CI, 1.001-3.419; P=0.049), and stage IV-V (HR =3.915; 95% CI, 1.843-8.316; P<0.001) according to CKD-EPI-CystC equation were confirmed to be independent prognostic factors for post-LT survival.
The pretransplant renal function evaluated by serum CystC was associated with mortality after LT and could be used for predicting post-transplant survival.
在终末期肝病模型(MELD)评分中,肾功能被认为与肝移植受者的预后密切相关。基于血清胱抑素C(CystC)的方程被认为比基于肌酐(Pcr)的方程在计算估计肾小球滤过率(eGFR)方面更为准确。因此,我们旨在评估慢性肾脏病流行病学协作组(CKD-EPI)-CystC方程估算的eGFR与移植后死亡率之间的关联。
2015年1月至2018年1月,在肝移植(LT)及其他临床参数评估前,收集了我们中心连续接受LT的307例患者的CystC数据。根据肾脏病改善全球预后(KDOQI)分类将患者分为四组。
根据CKD-EPI-CystC方程和KDOQI分类,117例患者(38.1%)为I期,76例(24.8%)为II期,85例(27.7%)为III期,29例(9.4%)为IV-V期。单因素和多因素分析后,MELD评分[风险比(HR)=1.035;95%置信区间(CI),1.006-1.066;P=0.018]、合并肝细胞癌(HR =2.314;95%CI,1.253-4.273;P=0.007)以及根据CKD-EPI-CystC方程得出的KDOQI III期(HR =1.850;95%CI,1.001-3.419;P=0.049)和IV-V期(HR =3.915;95%CI,1.843-8.316;P<0.001)被确认为LT后生存的独立预后因素。
血清CystC评估的移植前肾功能与LT后的死亡率相关,可用于预测移植后生存情况。